Armed robbery in Revesby1 天
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
manilatimes2 天
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount ...
In the past, Dr. Horowitz had been a paid consultant for Purple Biotech.
Le Lézard2 天
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival ...
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...